Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J.

Haematologica. 2017 Jul;102(7):1185-1191. doi: 10.3324/haematol.2017.164012. Epub 2017 Mar 24.

2.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
4.

Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.

Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, Spyropoulos AC, Hashmi SK.

Ann Hematol. 2016 Sep;95(9):1457-64. doi: 10.1007/s00277-016-2673-3. Epub 2016 Apr 22. Review.

PMID:
27103008
5.

Venous thromboembolism incidence in hematologic malignancies.

Kekre N, Connors JM.

Blood Rev. 2019 Jan;33:24-32. doi: 10.1016/j.blre.2018.06.002. Epub 2018 Jun 21. Review.

PMID:
30262170
6.

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR.

Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16.

7.

Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A.

Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.

8.

Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.

Rabian F, Porcher R, Sicre de Fontbrune F, Lioure B, Laplace A, Nguyen S, Tabrizi R, Vigouroux S, Tomowiak C, Maillard N, Suarez F, Delage J, Peffault de Latour R, Socié G; French Society of Bone Marrow Transplantation and Cell Therapy.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1721-1724. doi: 10.1016/j.bbmt.2016.05.022. Epub 2016 May 28.

9.

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.

Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V.

Haematologica. 2008 Dec;93(12):1852-8. doi: 10.3324/haematol.13033. Epub 2008 Oct 22.

10.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
11.

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.

Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.

12.

Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T; JSHCT GVHD Working Group.

Haematologica. 2016 Dec;101(12):1592-1602. Epub 2016 Aug 4.

13.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, Brunstein C, Bejanyan N, Arora M.

Biol Blood Marrow Transplant. 2016 May;22(5):879-83. doi: 10.1016/j.bbmt.2015.12.020. Epub 2015 Dec 29.

14.

Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.

Bryant A, Mallick R, Huebsch L, Allan D, Atkins H, Anstee G, Sabloff M, Scrivens N, Maze D, Bredeson C, Kekre N.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15.

15.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.

Solh M, Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2192-2198. doi: 10.1016/j.bbmt.2017.08.030. Epub 2017 Aug 30.

16.

Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

Kheav VD, Busson M, Scieux C, Peffault de Latour R, Maki G, Haas P, Mazeron MC, Carmagnat M, Masson E, Xhaard A, Robin M, Ribaud P, Dulphy N, Loiseau P, Charron D, Socié G, Toubert A, Moins-Teisserenc H.

Haematologica. 2014 Dec;99(12):1860-7. doi: 10.3324/haematol.2014.108407. Epub 2014 Aug 1.

17.

Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.

Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, Merli P, Pagliara D, Prete A, Zecca M.

Lancet Oncol. 2017 Aug;18(8):1126-1136. doi: 10.1016/S1470-2045(17)30417-5. Epub 2017 Jul 10.

PMID:
28705454
18.

Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.

Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F.

PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.

19.

Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.

Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1266-72. doi: 10.1016/j.bbmt.2015.02.024. Epub 2015 Mar 10.

20.

Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.

Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, Girdlestone J.

Cochrane Database Syst Rev. 2019 Jan 30;1:CD009768. doi: 10.1002/14651858.CD009768.pub2.

PMID:
30697701

Supplemental Content

Support Center